Making COPD a treatable disease-An integrated care perspective

Respiratory Medicine: COPD Update

Volumn 3, Issue 2, 2007, Pages 49-56

  van Schayck, C P ^a   Bindels, P J E ^b   Decramer, M ^c   Dekhuijzen, P N R ^d   Kerstjens, H A M ^e   Muris, J W M ^a   Asijee, G M ^f   Spreeuwenberg, C ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f Advanced Care Solutions and Insights for Care Optimization   (Netherlands)

Author keywords

Awareness; COPD; Disease management; Guidelines; Pathophysiology

Indexed keywords

ARTICLE; AWARENESS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; EXERCISE; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEALTH STATUS; HUMAN; INTEGRATED HEALTH CARE SYSTEM; OCCUPATIONAL EXPOSURE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING CESSATION;

EID: 34248584100     PISSN: 17450454     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmedu.2007.01.001     Document Type: Article

References (59)

1. van Schayck C.P., Loozen J.M., Wagena E., et al. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case finding study. BMJ 324 (2002) 1370-1374
2. Murray C.J.L., and Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
3. Pearson M. Raising the profile of COPD with healthcare decision-makers. Respir Med 96 Suppl C (2002) S1-S2
4. Pauwels R., Buist A., Calverley P., et al., on behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163 (2000) 1256-1276
5. Gamble E., Grootendorst D.C., Brightling C.E., et al. Anti-inflammatory effects of the phosphodiesterase 4 inhibitor cilomilast (Ariflo) in COPD. Am J Respir Crit Care Med 168 (2003) 976-982
6. Barnes N.C., Qiu Y.S., Pavord I.D., et al. Anti-inflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173 (2006) 736-743
7. Ferguson G.T. The ins and outs of breathing: an overview of lung mechanics. Eur Respir Rev 13 (2004) 89 30-34
8. Johnson M., and Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonsists in COPD. Chest 120 (2001) 258-270
9. Gosens R., Bos S.T., Zaagsma J., et al. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am J Respir Crit Care Med 171 (2005) 1096-1102
10. Bühling F., Lieder N., Reisenauer A., et al. Anti-inflammatory function of tiotropium mediated by suppression of acetylcholine-induced release of chemotactic activity. Eur Respir J 24 Suppl 48 (2004) 318s
11. Celli B.R., McNee W., and ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 (2004) 932-946
12. 1. The lung health study. JAMA 272 (1994) 1497-1505
13. Britton J., and Knox A. Helping people to stop smoking; the new smoking cessation guidelines. Thorax 54 (1999) 1-2
14. The tobacco use and dependence clinical practice guideline panel, staff, and consortium representatives. A clinical practice guideline for treating tobacco use and dependence. JAMA 283 (2000) 3244-3254
15. Janson C., Künzli N., de Marco R., et al. Changes in active and passive smoking in the European Community Respiratory Health Survey. Eur Respir J 27 (2006) 517-524
16. NIPO Market Research Institute. COPD: altijd gehandicapt (Dutch). Report nr. B1275; December 2002.
17. Brandt C.J., Ellegaard H., Joensen M., et al., for RYLUNG group. Effect of diagnosis of "smoker's lung". Lancet 349 (1997) 253
18. Levy M.K., Fletcher M., Price D.B., et al. International primary care respiratory group (ICPRG) guidelines: diagnosis of respiratory diseases in primary care. Prim Care Respir J 15 (2006) 20-34
19. Freeman D., Nordyke R.J., Isonaka S., et al. Questions for COPD diagnostic screening in a primary care setting. Respir Med 99 (2005) 1311-1318
20. Royal college of family physicians, Office of population censuses and surveys, Department of Health and Social Security. Morbidity statistics from general practice 1981-82. Third national study. Series MB5 no 1 London.
21. Tirimanna P.R.S., van Schayck C.P., den Otter J.J., et al. Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977?. Br J Gen Pract 46 (1996) 277-281
22. Hoogendoorn M., Rutten-van Mölken M.P.M.H., Hoogenveen R.T., et al. A dynamic population model of disease progression in COPD. Eur Respir J 26 (2005) 223-233
23. Bellamy D., Bouchard J., Henrichsen S., et al. International primary care respiratory group (ICPRG) guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 15 (2006) 48-57
24. Rutten F.H., Cramer M.J.M., Grobbee D.E., et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J 26 (2005) 1887-1894
25. Steuten L.M.G., Creutzberg E.C., Vrijhoef H.J.M., et al. COPD as a multicomponent disease: inventory of dyspnoea, underweight, obesity and fat free mass depletion in primary care. Prim Care Respir J 15 (2006) 581-586
26. Bestall J.C., Paul E.A., Garrod R., et al. Usefulness of the MRC dyspnoea scale as a measure of disability in patients with COPD. Thorax 54 (1999) 581-586
27. Celli B.R., Cote C.G., Marin J.M., et al. The body-mass index, airflow obstruction, dyspnoea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 10 (2004) 1005-1012
28. Mostert R., Goris A., Weling-Scheepers C., et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 94 (2000) 859-867
29. Seemungal T.A.R., Donaldson G.C., Paul E.A., et al. Effect of exacerbation on quality of life in patients with COPD. Am J Respir Crit Care Med 157 (1998) 1418-1422
30. Anthonisen N.R., Connett J.E., and Murray R.P. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med 166 (2002) 675-679
31. Pauwels R.A., Lofdahl C.G., Laitinen L.A., et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 340 (1999) 1948-1953
32. Burge P.S., Calverley P.M.A., Jones P.W., et al., on behalf of the ISOLDE study investigators. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320 (2000) 1297-1303
33. Vestbo J., Sørensen T., Lange P., et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353 (1999) 1819-1823
34. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343 (2000) 1902-1909
35. Decramer M., Celli B., Taskin D.P., et al. Clinical trial design considerations in assessing long-term functional impacts of Tiotropium in COPD: the UPLIFT trial COPD. J COPD 1 (2004) 303-312
36. Soriano J.B., Vestbo J., Pride N.B., et al. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20 (2002) 819-825
37. Soriano J.B., Kiri V.A., Pride N., et al. Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2 (2003) 67-74
38. Calverley P., Celli B., Anderson J., et al. The TORCH (towards a revolution in COPD health study): salmeterol/fluticasone propionate (SFC) improves survival in COPD over 3 years. Eur Respir J 28 Supp. 50 (2006) 34s
39. Newton M.F., O'Donnell D.E., and Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 121 (2002) 1042-1050
40. O'Donnell D.E., Lam M., and Webb K.A. Measurement of symptoms, lung hyperinflation and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 (1998) 1557-1565
41. O'Donnell D.E., Flüge T., Gerken F., et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23 (2004) 832-840
42. Gross N.J. Chronic obstructive pulmonary disease outcome measurements. What's important? What's useful?. Proc Am Thorac Soc 2 (2005) 267-271
43. Mahler D.A., and Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest 93 (1988) 580-586
44. Mahler D.A., Weinberg D.H., Wells C.K., et al. The measurement of dyspnoea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85 (1984) 751-758
45. Pitta F., Troosters T., Spruit M.A., et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 (2005) 972-977
46. van der Molen T., Willemse B.W.M., Schokker S., et al. Development, validity and responsiveness of the clinical COPD questionnaire. Health Qual Life Outcomes 1 (2003) 13-22
47. Calverley P., Pauwels R., Vestbo J., et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361 (2003) 449-456
48. Szafranski W., Cukier A., Ramirez A., et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21 (2003) 74-81
49. Brusasco V., Hodder R., Miravitles M., et al. Health outcomes following treatment for six months with once daily tiotropium compared to twice daily salmeterol in patients with COPD. Thorax 58 (2003) 399-404
50. Vincken W., van Noord J.A., Greefhorst A.P.M., et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 19 (2002) 209-216
51. Troosters T., Gosselink R., Derycke P., et al. Pulmonary rehabilitation improves activities of daily living (ADL), measured with a triaxial activity monitor. Am J Respir Crit Care Med 165 (2002) A738
52. American Thoracic Society. Pulmonary Rehabilitation-1999. Official statement of the ATS. Am J Resp Crit Care Med 159 (1999) 1666-1682
53. Chavannes N., Vollenberg J.J.H., van Schayck C.P., et al. Effects of physical activity in mild to moderate COPD: a systematic review. Br J Gen Prac 52 (2002) 574-578
54. Spruit M.A., Gosselink R., Troosters T., et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58 (2003) 752-756
55. Niewoehner D.E., Rice K., Cote C., et al. Prevention of exacerbations of chronic obstructive pulmonary disease with triotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 143 (2005) 317-326
56. Dusser D., Bravo M.-L., Iacono P., and on behalf of the MISTRAL study group. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur Respir J 27 (2006) 547-555
57. The American heritage. Dictionary of English language, fourth ed. Houghton Miffin Dictionary, 2004.
58. Buist A.S. Guidelines for the management of COPD. Respir Med 96 Suppl C (2002) S11-S16
59. The National Collaborating Centre for Chronic Conditions. National clinical guideline on management of COPD in adults in primary and secondary care. Thorax 59 Suppl 1 (2004) 1-232